The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device for identifying eligible patients. Approval of sotorasib with panitumumab was based on ...

The FDA also approved the therascreen KRAS RGQ PCR Kit (QIAGEN GmbH) as a companion diagnostic device to aid in identifying patients with colorectal cancer whose tumors harbor KRAS G12C mutations and ...

The global respiratory diagnostics market, valued at US$ 5.85 billion in 2023, is forecasted to grow at a robust CAGR of 6.5%, reaching US$ ...

6) In brief, Roche cobas e411 (Roche Diagnostics GmbH) was utilized to measure the concentration ... In brief, cfDNA was extracted from plasma using QIAamp Circulating Nucleic Acid Kit (QIAGEN) ...

AAV vectors were produced by co-transfection of pDP8.ape (PlasmidFactory GmbH & Co. KG, Bielefeld Germany ... Total DNA extraction from livers was performed using the QIAamp DNA Mini Kit (Qiagen, ...

Cross sections of the muscle tissue were cut using a cryostat microtome (Leica CM1100, Leica Microsystem Nussloch GmbH, Germany ... placed in 1.7 ml tube and homogenized with the TissueLyzer (Qiagen).

In a report released today, Falko Friedrichs from Deutsche Bank maintained a Buy rating on Qiagen (QGEN – Research Report). The company’s ...

Kepler Capital analyst Maja Pataki maintained a Hold rating on Qiagen (QGEN – Research Report) on February 6 and set a price target of €42.17.

operating income margin improvement of at least 150 basis points VENLO, The Netherlands, February 05, 2025--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced ...

EPS; adj. operating income margin improves 1.8 percentage points to 28.7% QIAGEN expects the solid growth pace in H2 2024 to continue in 2025. Net sales are expected to rise about 4% CER (and core ...

QIAGEN N.V.’s QGEN long-term business strategy focuses on forming partnerships for the development, commercialization, marketing and distribution of existing and future products. The company ...